Intravenous Pentamidine for Pneumocystis Jirovecii Pneumonia

• Status: Completed
• Trial end date: 2016-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The main objective of this study is to assess the safety of administering intravenous (IV) pentamidine for Pneumocystis jirovecii pneumonia (PJP) prophylaxis in adult inpatients with hematologic malignancies and stem cell transplant recipients. There will also be an assessment of patient satisfaction associated with intravenous pentamidine PJP prophylactic therapy.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Illinois at Chicago
• Treatments: Pentamidine

Criteria

Inclusion Criteria:

• Adults (18 years or older)

• Hematologic malignancy diagnosis or stem-cell transplant recipient

• Eligible for PJP prophylaxis therapy at time of enrollment as per institutional guidelines in compliance with NCCN guidelines. These patients include:

• Acute myeloid leukemia patients receiving induction and consolidation (first line and relapsed/refractory)

• Acute lymphoid leukemia patients receiving HyperCVAD/R (cyclophosphamide, vincristine, doxorubicin, dexamethasone, methotrexate, cytarabine, rituximab)

• Lymphoma patients receiving ICE (ifosfamide, carboplatin, etoposide), DA-R-EPOCH (dose-adjusted rituximab, etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin), and other inpatient lymphoma regimens

• Patients receiving other inpatient chemotherapy regimens that are given on a monthly basis

• Patients who have received an allogeneic stem cell transplant

• Have given informed consent

• May have previously received inhaled or IV pentamidine

Exclusion Criteria:

• Pregnancy

• Prisoners

• Patients with a documented allergy or hypersensitivity to pentamidine.